Gene test may spare breast cancer patients from unnecessary radiation

NCT ID NCT04069884

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether a genetic test called RecurIndex can identify breast cancer patients with cancer in their lymph nodes who can safely skip radiation to the lymph nodes. The goal is to reduce side effects like arm swelling and pain without increasing the risk of cancer coming back. The trial will enroll 540 patients and follow them for several years to compare outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regional nodal irradiation (radiation therapy)
What this could lead to: If successful, this could allow many breast cancer patients to safely skip radiation to the lymph nodes, reducing side effects like arm swelling and pain.
What could go wrong: This is an early-stage validation study with 540 participants, so results may not apply to all patients. The genetic test might not accurately predict who needs radiation, potentially increasing recurrence risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER RADIATION

Contacts and locations

Locations

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITING

Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.